Abstract
Gene and cell therapy, including gene editing approaches have already begun to show important evidence of clinical efficacy in early stage human trials for inherited immune deficiency disorders and in some cases of HIV/AIDS. Human Gene Therapy is now seeking original papers and review articles that describe the design, optimization, and application of such therapies, including, but not limited to, the following technologies: Lentiviral and retroviral gene therapy for inherited immune deficiency disorders CRISPR-Cas9 mediated gene therapy for inherited immune deficiency disorders Gene therapy approaches to HIV prevention and treatment CRISPR-Cas9 and other genome editing strategies to convey resistance to HIV infection Gene therapy, oligonucleotide therapy and gene editing strategies to eliminate HIV reservoirs
Demonstrations of the utility of one or more of such technologies in animal models and clinical trials is of great interest. As stated above, both scholarly review articles and original papers (meeting our usual submission guidelines for these categories) are welcome.
For questions regarding submissions or for technical assistance, contact HGT's Managing Editor: Mary Mazzanti at